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The ability to preselect the donor genotype of iPSC lines provides important opportunities for immunematch-
ing in cell therapy. Here we propose that an international assessment should bemade of how immune incom-
patibility can best bemanaged and how a network of GMP HLA homozygous haplobanks could be operated.Much has beenwritten about the potential
contribution of human pluripotent-stem-
cell-line-derived cellular therapeutics
to the future realization of regenerative
medicine. However, the development of
clinical cellular therapeutics from these
sources requires attention to issues nor-
mally associated with blood, tissue, and
organ transplantation, such as donor
consent, selection and screening, and
immune compatibility, as well as issues
related to clinical good manufacturing
practice (GMP), quality assurance, and
regulatory compliance. A key clinical
issue will be the extent to which pluripo-
tent-stem-cell-line-derived cellular thera-
peutics are likely to be immunologically
compatible with patients. The ability to
preselect the donor genotype of induced
pluripotent stem cell (iPSC) lines provides
opportunities for immune matching that
were not available with embryo-derived
pluripotent cell (hESC) lines (Taylor et al.
2012; Rao et al. 2012). While it is possible
that clinical GMP-grade autologous iPSC
lines could be derived on an individual
basis, it seems unlikely that these will be
used as a source for large numbers of
patients in the near future, given the time
and cost required to produce clinical
GMP cell lines and to differentiate these382 Cell Stem Cell 13, October 3, 2013 ª201into cells and tissues of clinical utility. It
is likely, therefore, that a bank of alloge-
neic clinical GMP cell lines will be required
to allow the field to develop over the next
few years, raising the issues of how such a
bank, or network of banks, could be es-
tablished and, in particular, how immune
incompatibility can best be managed.
Solid organ transplantation benefits
from at least partial HLA matching and
systemic immune suppression in order
to reduce the incidence and severity of
graft rejection. In the case of hematopoi-
etic stem cell transplantation (HSCT),
even more stringent HLA matching is
required to reduce the risk of both rejec-
tion and graft versus host disease
(GvHD), though GvHD should not occur
with hESC or iPSC-derived cell or tissue
transplants due to the lack of donor
T cells in the graft. Immune suppression
carries long-term side effects and the
risks of recurrent infection, some forms
of neoplasia, and cardiovascular disease.
Despite the fact that pluripotent stem cell
lines and cells derived therefrom appear
to demonstrate low expression of HLA
antigens (Drukker et al. 2006), it is clear
that differentiated cells do generate an
allogeneic response as seen by T cell pro-
liferation and cellular apoptosis against3 Elsevier Inc.iPSC-derived tissue-specific cells in
mice (Guha et al. 2013). Further evidence
of immune reactivity against allogeneic
cell therapy targets is provided by the
observation that cytotoxic reactivity and
alloantibodies can be produced against
mesenchymal stromal cells (Schu et al.,
2012) and the clinical finding that upon
cessation of immunosuppression, HLA
antibodies are commonly found in recipi-
ents of HLA-mismatched islet transplants
(Campbell et al., 2007). Immune T cell
activation against human cell, tissue,
and organ grafts occurs via both direct
and indirect antigen presentation. The
direct route involves antigen-presenting
cells (APCs) within the graft itself whereas
the indirect route requires the processing
and presentation of foreign proteins by
the recipient’s own APCs. It is likely that
in cellular therapeutics the indirect route
will predominate due to the absence of
donor APCs in the cultured cells. How-
ever, the indirect route of activation still
provides a potent mechanism for the initi-
ation of the alloimmune response, and the
immune state itself is dynamic—other
stressors can induce rejection at a later
stage. In addition, NK cells are also likely
to contribute to the rejection of mis-
matched tissues, particularly single-cell
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(killer cell immunoglobulin-like receptors:
KIRs) recognize ‘‘self’’ HLA, but NK cells
become activated by the absence of
‘‘self’’ (thus evading T cell recognition) as
seen with certain cancers, viruses, and
HLA-mismatched allogeneic HSCT. Thus
for the production of cellular therapeutics
where long-term integration of cells is
desired, some degree of HLA matching
of allogeneic pluripotent stem cell lines
to the potential recipient population is
highly desirable. The questions then
become, ‘‘What degree of HLA matching
is necessary, and what is the optimal
strategy for the design of a cell bank
which could serve these requirements?’’
Several levels of immune compatibility
need to be considered:
d Carbohydrate blood group antigens
such as the ABO system are ex-
pressed by all human cells, and indi-
viduals who lack expression of the
relevant glycosyl-transferases pro-
duce naturally occurring anti-A and
anti-B isohaemagglutinins, which
can cause hyperacute rejection of
an incompatible cellular graft.
d HLA incompatibility between donor
cells, tissues, or organs and the
recipient gives rise to rejection.
One would therefore wish to match
as many HLA-class I and II loci as
is practical in order to minimize this
risk and the degree of immuno-
suppression required. Over 9,000
alleles have been identified within
the HLA system, which makes this
difficult to achieve, but linkage
disequilibrium within the HLA region
raises the possibility that individuals
are likely to exist that are homo-
zygous for common HLA haplo-
types. Such individuals will produce
stem cell lines that are HLA compat-
ible with a high proportion of the
population.
d It should be borne in mind that even
HLA-A, -B, and -DR matched cells,
tissues, and organsmay be rejected
if there aremismatches between the
donor and recipient for other HLA
loci or minor histocompatibility anti-
gens. Because many of the latter
reside on the Y chromosome, it
would be preferable to build the
HLA haplobank from female donors
where possible, although it shouldbe noted that there are potential
problems with reactivation of the X
chromosome in some iPSC lines.
d Finally, there is evidence that plurip-
otent stem cells and their derivates
can be immunogenic as a result
of antigen rearrangements arising
from the derivation and culture
protocols.
On the basis of first field HLA typing
(two-digit typing), Taylor et al. (2012) first
estimated that just 10 cell lines homozy-
gous for common HLA types selected
from 10,000 individuals could provide an
HLA antigen match at HLA-A, HLA-B,
and HLA-DR for at least 37.7% of the
UK population and a potentially beneficial
match for 67.4%. Further work from this
group calculated the optimal combination
of homozygous HLA types that would
match the UK population and identified
the 150 most useful homozygous HLA
types present among 17 million HLA-
typed volunteer stem cell donors regis-
tered on Bone Marrow Donors Worldwide
that could provide a match for 93% of the
UK population (Taylor et al. 2012) when
the subject of allele-level matching was
also addressed. Nakatsuji et al. have esti-
mated that 30 homozygous cell lines
selected from 15,000 individuals would
match 82.2% of the Japanese population
at the HLA antigen level for HLA-A, HLA-
B, and HLA-DR, with 50 homozygous
lines selected from 24,000 individuals
matching 90.7% of that population
(Nakatsuji et al. 2008). Similarly, Okita
et al. estimated that, when focusing on
higher-resolution HLA-allele-level match-
ing, 140 homozygous lines selected from
160,000 individuals would provide a
match for 90% of the Japanese popula-
tion (Okita et al. 2011). However, these
studies in relatively homogenous popula-
tions underestimate the challenge in pop-
ulations with more diverse ancestral and
racial backgrounds.
Gourraud et al. (2012) have used a
probabilistic model to estimate the num-
ber of donors required to construct a hap-
lobank in populations from four different
ancestral backgrounds. A bank of 20
homozygous cell lines would require the
screening of some 26,000 Northern Euro-
peans and would match more than 50%
of that population, but would require the
screening of 110,000 African Americans
to achieve a match of 22% of that popula-Cell Stem Cell 1tion. A bank of 100 homozygous cell lines
from each of these populations would
match around 78% of Northern Euro-
peans, 63% of Asians, and 52% of
Hispanics, but only 45% of African
Americans.
Given the large numbers of individuals
who would need to be screened, particu-
larly if gender and blood group are taken
into account, we suggest that established
cohorts of HLA-typed individuals, such as
the more than 22 million people on world-
wide hematopoietic stem cell donor regis-
tries, cord blood banks, and platelet
apheresis panels (Taylor et al. 2012, Rao
et al. 2012), would provide a cost-effec-
tive way to identify and contact donors
who have already consented to donate
blood or tissue for clinical purposes
and have a high level of traceability. In
addition, HLA types can be imputed
from genome-wide association studies
(GWAS) (Dilthey et al. 2013) that have
already been performed for millions of
people of most major ethnic groups. It
would be helpful if major health founda-
tions could support further GWAS, partic-
ularly in regions of high genetic diversity,
smaller ethnic groups, and peoples from
underdeveloped countries where estab-
lished HLA-typed clinical panels are less
common. Work to establish a blood-
derived iPSC bank has been initiated in
Japan (S. Yamanaka, personal communi-
cation) and is under consideration in the
US and Europe.
An international network of mutually
recognized iPSC banks would enable
the broadest access to this new genera-
tion of cellular therapeutics for people of
different ancestral and ethnic back-
grounds. However, a number of chal-
lenges will have to be addressed if this
vision is to be realized.
First, informed consent is normally
given for direct clinical use of platelet or
hematopoietic progenitor cell donations
by the donor or, in the case of cord blood,
by his/her parents. It is likely that further or
more extensive consent will be required
for cell donation for iPSC generation given
that a permanent cell line will be estab-
lished and disseminated and may be
subject to as yet unforeseen academic,
clinical, and commercial developments.
Second, since it is possible that a single
cell line could be used to generate
different cellular therapies that may them-
selves be used to treat many patients over3, October 3, 2013 ª2013 Elsevier Inc. 383
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Foruma prolonged period of time, there is a risk
of amplification of the adverse effects of
an infection such as BSE or of genetic
abnormality present in the donor. Thought
therefore needs to be given to the extent
of donor selection and screening. Estab-
lished, new, and emergent infections will
need to be considered along with those
agents that may be nonpathogenic in
normal individuals but give rise to disease
in subsets of patients such as those
who are immunosuppressed. Moreover,
genetic polymorphism in the donor could
conceivably give rise to failure of a cellular
therapeutic derived therefrom or dissemi-
nated disease in recipients. Third, given
that traceability will have to be retained
between donor and recipients for many
years, if not decades, the extent to which
donors should be informed of ‘‘abnormal-
ities’’ discovered in their cell lines—partic-
ularly where these may have implications
for the health of the donor, his/her family,
or the wider public health—should be
addressed. Finally, since it is likely that
a number of different facilities will be
engaged in the manufacture and banking
of iPSCs, it is essential that agreement is
reached over (inter alia) quality control
standards of derivation, characteriza-
tion, and monitoring of the cell lines
themselves, including the use of com-
mon nomenclature, identity and potency
assays, and reference standards. It is crit-384 Cell Stem Cell 13, October 3, 2013 ª201ical that these cell lines are acceptable
across the range of international regula-
tory bodies if cellular therapeutics derived
therefrom are to have general clinical
applicability.
Given that it is now possible to impute
HLA types from GWAS, that international
HLA-typed panels, registries, and banks
already exist, and that protocols for the
derivation of iPSC from such samples
have been verified, we suggest that now
is the time to start putting together the in-
ternational collaboration needed to reach
agreement on these issues before the
methods required for large-scale produc-
tion of cells at clinical grade are estab-
lished. We note that several nonthera-
peutic-grade iPSC banking efforts that
will include hundreds or thousands of
lines are well underway, indicating that
both the will and the infrastructure exist
to develop a relatively small registered
and quality-controlled panel uniquely
dedicated to cell therapy. Such an initia-
tive would enable the global application
of this new generation of regenerative
therapeutics in a timely and equitable
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